Mitchell JA, Ventura HO, Mehra MR. Early recognition and treatment of hypertensive heart disease. Curr Opin Cardiol 2005; 20: 282-9.
Waeber B, Detry J-M, Dahlöf B, et al. Felodipine–metoprolol combination tablet: A valuable option to initiate antihypertensive therapy? Am J Hypertens 1999; 12: 915-20.
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-23.
Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Card 2007; 22: 316-20.
Cordero A, Bertomeu-Martínez V, Mazón P, et al. Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease. Rev ESP Cardiol 2011; 64: 587-93.
Fogari R, Zoppi A, Lusardi P, et al. Effects of benazepril alone and in combination with hydrochlorothiazide in comparison with felodipine extended release in elderly patients with mild-to-moderate essential hypertension. Curr Ther Res 1998; 59: 246-56.
Achilli F, Buono G, Di Fraia S, et al. Acute and chronic effects of felodipine extended release and amlodipine in patients with exertional angina: A double-masked, clinical comparison. Curr Ther Res 1996; 57: 523-36.
Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009; 8CD001841
Pestana M. Hypertension in the elderly. Int Urol Nephrol 2001; 33: 563-9.
Emanuelsson H, Egstrup K, Nikus K, et al. Antianginal efficacy of the combination of felodipine-metoprolol 10/100 mg compared with each drug alone in patients with stable effort-induced angina pectoris: A multicenter parallel group study. Am Heart J 1999; 137: 854-62.
Chen J, Ren Y, Tang Y, et al. Acupuncture therapy for angina pectoris: A systematic review. J Trad Chin Med 2012; 32: 494-01.
Deckers JW. Classification of myocardial infarction and unstable angina: A re- assessment. Int J Cardiol 2013; 167: 2387-90.
Heart and Stroke Facts 1996. Statistical Supplement Dallas TX: American Heart Association.
Schoen M, Tanzi MG. Role of calcium channel blockers in treatment of hypertension. Today 2008; 14: 50-65.
Ljung B. Vascular selectivity of felodipine. Drugs 1985; 29: 46-58.
Freher M, Challapalli S, Pinto JV, et al. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Prob Cardiol 1999; 24: 230-40.
Gradman AH. The evolving role of calcium channel blockers in the treatment of angina pectoris: Focus on felodipine. Can J Cardiol 1995; 11: 14B-21B.
Hedner T, Elmfeldt D, Schenck H, et al. Glucose tolerance in hypertensive patients during treatment with the calcium antagonist, felodipine. Br J Clin Pharmacol 1987; 24: 145-9.
Mann S. Dihydropyridines, felodipine, and pharmac. N Z Med J 2005; 118: U1569.
Little WC, Cheng C-P, Elvelin L, et al. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: Focus on felodipine. Cardiovasc Drugs Ther 1995; 9: 657-63.
Edgar B, Regardh C, Attman P, et al. Pharmacokinetics of felodipine in patients with impaired renal function. Br J Clin Pharmacol 1989; 27: 67-74.
Wade JR, Sambol NC. Felodipine population dose-response and concentration-response relationships in patients with essential hypertension. Clin Pharmacol Ther 1995; 57: 569-81.
Blychert E, Edgar B, Elmfeldt D, et al. Plasma concentration-effect relationships for felodipine: A meta-analysis. Br J Clin Pharmacol 1991; 31: 15-24.
Edgar B, Lundborg P, Regårdh C. Clinical pharmacokinetics of felodipine. Drugs 1987; 34: 16-27.
Blychert E, Edgar B, Elmfeldt D, et al. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991; 31: 15-24.
Li Y, Yin Y, Sun Z, et al. Sensitive and rapid quantification of felodipine by high- performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and its pharmacokinetics in healthy chinese volunteers. Chem Res Chinese Univ 2006; 22: 479-83.
Hulthén UL, Katzman PL. Renal effects of acute and long-term treatment with felodipine in essential hypertension. J Hypertens 1988; 6: 2231-7.
Regårdh C, Edgar B, Olsson R, et al. Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol 1989; 36: 473-9.
Lundahl J, Regårdh C, Edgar B, et al. Effects of grapefruit juice ingestion– pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139-45.
Bailey D, Arnold J, Bend J, et al. Grapefruit juice-felodipine interaction: Reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995; 40: 135-40.
Takanaga H, Ohnishi A, Matsuo H, et al. Pharmacokinetic analysis of felodipine– grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000; 49: 49-58.
Wiklund I, Dimenäs E, Partridge S. Effects of felodipine extended release on quality of life—an analysis of four clinical trials. Curr Ther Res 1995; 56: 81-94.
Andersson O, Bengtsson C, Elmfeldt D, et al. Short‐term effects of felodipine, a new dihydropyridine, in hypertension. Br J Clin Pharmacol 1984; 17: 257-63.
Bossini A, Veroli C, Cavallotti G, et al. Felodipine ER formulation in the treatment of mild hypertension: Efficacy and tolerability vs placebo. Br J Clin Pharmacol 1990; 30: 567-71.
Bainbridge A, Macfadyen R, Stark S, et al. The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharmacol 1993; 36: 323-30.
Lassen E, Frimodt-Møller J, Ahlstrøm F, et al. Antihypertensive efficacy and safety of felodipine compared with nitrendipine in mild to moderate hypertension. Curr Ther Res 1993; 53: 654-64.
Elliott WJ, Montoro R, Smith D, et al. Comparison of two strategies for intensifying antihypertensive treatment. Am J Hypertens 1999; 12: 691-6.
Lin M, Arnold Chan K, Wang C, et al. Effects of low-dose treatment with felodipine versus fosinopril in Chinese patients with non-ischemic heart failure and normal blood pressure: a double-blind, randomized, crossover study. Curr Ther Res 2004; 65: 204-21.
Gavras HP. Issues in hypertension: Drug tolerability and special populations. Am J Hypertens 2001; 14: 231S-6S.
van der Krogt JP, Brand R, Dawson EC. Amlodipine versus extended-release felodipine in general practice: A randomized, parallel-group study in patients with mild-to-moderate hypertension. Curr Ther Res 1996; 57: 145-58.
Hosie J, Langan J, Scott M, et al. Effectiveness and tolerability of felodipine once daily and nifedipine twice daily as monotherapies for mild hypertension. J Drug Dev 1992; 5: 129-36.
Gradman AH, Cutler NR, Davis PJ, et al. Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine err in the treatment of hypertension. Clin Ther 1998; 20: 527-38.
Nalbantgil S, Zoghi M, Özerkan F, et al. Comparison of candesartan and felodipine alone and combined in the treatment of hypertension: A single-center, double-blind, randomized, crossover trial. Curr Ther Res 2003; 64: 380-8.
Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Heart 2002; 15: 544-9.
Frishman WH, Hainer JW, Sugg J. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release: Results of the metoprolol succinate-felodipine antihypertension combination trial (m-fact). Am J Hypertens 2006; 19: 388-95.
Fagan TC. Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. The felodipine ER in the elderly versus young working group. J Am Geriatr Soc 1997; 45: 712-7.
Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18: 548-53.
Falkner B, Daniels SR. Summary of the fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-76.
Evans CA, Jolivette LJ, Nagilla R, et al. Extrapolation of preclinical pharmacokinetics and molecular feature analysis of —discovery-like‖ molecules to predict human pharmacokinetics. Drug Metab Dispos 2006; 34: 1255-65.
Hardy B, Bartle W, Myers M, et al. Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine. Br J Clin Pharmacol 1988; 26: 557-62.
Dunselman P, Edgar B, Scaf A, et al. Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure. Br J Clin Pharmacol 1989; 28: 45-52.
Carruthers S, Vint-Reed C. Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Clin Invest Med 1993; 16: 386-94.
Cheung BM, Lau C-P, Wu B-Z. Amlodipine, felodipine, and isradipine in the treatment of chinese patients with mild-to-moderate hypertension. Clin Ther 1998; 20: 1159-69.